ENDPOINTS

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Ampersand Biomedicines, a biotech working on medicines "similar in principle" to antibody-drug conjugates, has secured $65 million in a Series B round. Eli Lilly took part in the funding round alongside Flagship Pioneering, which ...

Mar 19, 2025 - 12:01
 0
Flagship's Ampersand gets Eli Lilly's support in $65M Series B
Ampersand Biomedicines, a biotech working on medicines "similar in principle" to antibody-drug conjugates, has secured $65 million in a Series B round. Eli Lilly took part in the funding round alongside Flagship Pioneering, which ...
Read More

Tags:

Previous Article

The AI buffet: GPT, Gemini, Claude, and more for life—here’s how

Next Article

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Related Posts

Post-Hoc: China tensions both help and hurt Illumina

Post-Hoc: China tensions both help and hurt Illumina

Feb 9, 2025  0

Curevo gets $110M for a shot against Shingrix, gets Moncef Slaoui and Tal Zaks on board

Curevo gets $110M for a shot against Shingrix, gets Mon...

Mar 17, 2025  0

Legend to double Carvykti production as it targets blockbuster status 

Legend to double Carvykti production as it targets bloc...

Mar 12, 2025  0